

Table 1**Clinical characteristics of patients with CAR T therapy**

Cases	Gender	Age(years)	Diagnosis	Number of previous therapies(Regimens)
1	M	28	AML	2(DA,DAC)
2	F	26	MS(left thigh)	2(DA,DAC+EP)
3	F	37	extramedullary relapse of AML(left breast)	3(IA,HAA,DA)
4	M	31	T-LBL	3(BFM-95)

M=male; F=female; DA=Daunorubicin+Cytarabine; DAC=deoxycytidine; DPA=Vincristine+Daunorubicin+Prednisone+L-asparagine; IA=Idarubicin+Cytarabine; HAA=Hyperharringitrine+Cytarabine+Arubicin; EP=VP-16+cis-platinum(PDD); BFM-95=Berlin-Frankfurt-Munster-95

Table 2**Details of clinical results of patients with CAR-T treatment**

Cases	CAR T cells infused/Kg($\times 10^6$)	Best response	PFS(months)	OS(months)	Survival status
1	$1 \times 10^6/\text{kg}$	CR	2	5	alive
2	$4 \times 10^6/\text{kg}$	SD	2	2	alive
3	$3 \times 10^6/\text{kg}$	SD	3	3.5	alive
4	$4 \times 10^6/\text{kg}$	PR	1	3	dead

PR=partial response; CR=complete remission; SD=stable disease

Table 3**Toxicity related to CAR T treatment**

Cases	CRS	Neurological toxicity	Tocilizumab use	Glucocorticoid use
1	None	None	No	No
2	Grade 2	None	Yes	Yes
3	Grade 2	None	Yes	No
4	None	None	No	No

Table 4**Relationship between CRS occurrence and cytokine expression level**

Cases		IL-6 (0-5.90pg/ml)					CRP(0-10mg/L)					Serum Ferritin (male: 20-300ug/L; female: 10-120ug/L)				
	CRS	d0	d1	d3	d7	D14	d0	d1	d3	d7	D14	d0	d1	d3	d7	D14
1	None	3.07	2.15	<2	3.21	4.63	36	9.97	11.52	9.47	5.57	1294	1399	1327	1218	1446
2	Grade 2	2.72	>1000	57.4	27.4	>1000	2.7	90.8	16.4	2.98	1.58	265	228	297	109	173
3	Grade 2	3.66	58.6	>1000	363	677	15.49	15.75	50.1	48.06	35.08	178	151	347	237	251
4	None	3.07	5.48	7.77	3.89	16.8	6.2	29.2	16.2	24.2	24.9	690	530	593	532	926